ClinicalTrials.gg

Program

perflutren

Also written as “NH002 (Perflutren Lipid Microspheres) Injectable Suspension”, “DEFINITY®” and “Perflutren Lipid Microsphere Injectable Suspension”.

Its studies are mostly in Heart Diseases · Coronary Artery Disease · Pulmonary Heart Disease · Cardiovascular Diseases · Ischemic Stroke, led by 3 companies.

Furthest: phase 4, since Sep 9, 20059 company-led studies, 2 open or runningNext primary completion: Feb 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Lantheus50 open or runningphase 4since Sep 9, 2005Sep 9, 2005none ahead
Trust Bio-sonics32 open or runningphase 3since Jan 21, 2025Nov 6, 2019Feb 2027phase 3 · NCT06815627
ImaRx Therapeutics10 open or runningphase 2since Jul 25, 2007Jul 25, 2007none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 9, 2005First study: phase 4 study in Coronary Artery DiseaseNew to LantheusLantheus · NCT00162370 · 400 enrolled · United States
  2. Jul 25, 2007ImaRx Therapeutics's first study: phase 2 study in Ischemic StrokeNew to ImaRx TherapeuticsImaRx Therapeutics · NCT00507806
  3. Feb 20, 2008Phase 4 study in Cardiovascular DiseasesLantheus · NCT00625365 · 1,060 enrolled · United States
  4. Jun 4, 2009Phase 4 study in Pulmonary Heart DiseaseLantheus · NCT00918866 · 32 enrolled · United States
  5. Jun 6, 2018Phase 3 study in Heart DiseasesLantheus · NCT03571672 · 153 enrolled · United States
  6. Sep 28, 2018Phase 3 study in Heart DiseasesLantheus · NCT03719612 · 160 enrolled · United States
  7. Nov 6, 2019Trust Bio-sonics's first study: phase 2 study in Heart DiseasesNew to Trust Bio-sonicsTrust Bio-sonics · NCT04185246 · 36 enrolled · Taiwan
  8. Jan 21, 2025Phase 3 study in Heart DiseasesTrust Bio-sonics · NCT06815627 · 150 enrolled · Taiwan
  9. Jul 28, 2026Phase 3 study in Heart DiseasesTrust Bio-sonics · NCT07740421 · 150 planned

Ahead

  1. Feb 2027Primary completion: phase 3 study in Heart DiseasesTrust Bio-sonics · NCT06815627
  2. Jul 2027Primary completion: phase 3 study in Heart DiseasesTrust Bio-sonics · NCT07740421

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07740421Heart Diseases3Not yet recruitingTrust Bio-sonicsJul 2027150
NCT06815627Heart Diseases · Taiwan3Active, not recruitingTrust Bio-sonicsFeb 2027150
NCT04185246Heart Diseases · Taiwan2CompletedTrust Bio-sonicsJul 1, 202036
NCT03719612Heart Diseases · United States3CompletedLantheusJan 9, 2020160
NCT03571672Heart Diseases · United States3CompletedLantheusAug 30, 2019153
NCT00918866Pulmonary Heart Disease · United States4CompletedLantheusDec 200932
NCT00625365Cardiovascular Diseases · United States4CompletedLantheusMay 20091,060
NCT00507806Ischemic Stroke2TerminatedImaRx Therapeutics
NCT00162370Coronary Artery Disease · United States4CompletedLantheusSep 2012400

How it is read

Names in the registry

  • “NH002 (Perflutren Lipid Microspheres) Injectable Suspension”, 3 entries
  • “DEFINITY®”, 2 entries
  • “Perflutren Lipid Microsphere Injectable Suspension”, 1 entry
  • “DEFINITY”, 1 entry
  • “Definity”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.